[Bortezomib-induced acute neutrophilic dermatosis].
BACKGROUND
Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients.


METHODS
We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present.


CONCLUSIONS
The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.
Tanguy-Schmidt
A
A
Service des maladies du sang, CHU d'Angers, 49933 Angers cedex 09, France.
Avenel-Audran
M
M
Croué
A
A
Lissandre
S
S
Dib
M
M
Zidane-Marinnes
M
M
Moles
M-P
MP
Hunault-Berger
M
M
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology*; D016463:Sweet Syndrome / Q000139:chemically induced / Q000473:pathology
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib